These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22432116)

  • 21. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
    Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
    High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
    So WY; Ozaki R; Chan NN; Tong PC; Ho CS; Lam CW; Ko GT; Chow CC; Chan WB; Ma RC; Chan JC
    Hypertension; 2004 Sep; 44(3):294-9. PubMed ID: 15249544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched nondiabetic patients with end-stage renal disease from a single dialysis center from 1991 to 1997.
    Biesenbach G; Hubmann R; Grafinger P; Stuby U; Eichbauer-Sturm G; Janko O
    Diabetes Care; 2000 Dec; 23(12):1860-2. PubMed ID: 11128374
    [No Abstract]   [Full Text] [Related]  

  • 27. Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort.
    Hellemons ME; Denig P; de Zeeuw D; Voorham J; Lambers Heerspink HJ
    Nephrol Dial Transplant; 2013 Mar; 28(3):706-15. PubMed ID: 23262433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.
    Skupien J; Smiles AM; Valo E; Ahluwalia TS; Gyorgy B; Sandholm N; Croall S; Lajer M; McDonnell K; Forsblom C; Harjutsalo V; Marre M; Galecki AT; Tregouet DA; Wu CY; Mychaleckyj JC; Nickerson H; Pragnell M; Rich SS; Pezzolesi MG; Hadjadj S; Rossing P; Groop PH; Krolewski AS
    Diabetes Care; 2019 Jan; 42(1):93-101. PubMed ID: 30455333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
    Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
    Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in survival between black and white patients with diabetic end-stage renal disease.
    Cowie CC; Port FK; Rust KF; Harris MI
    Diabetes Care; 1994 Jul; 17(7):681-7. PubMed ID: 7924777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
    Saulnier PJ; Dieter BP; Tanamas SK; McPherson SM; Wheelock KM; Knowler WC; Looker HC; Meek RL; Nelson RG; Tuttle KR
    Am J Nephrol; 2017; 46(4):276-284. PubMed ID: 28934744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991 2005).
    Villar E; Chang SH; McDonald SP
    Diabetes Care; 2007 Dec; 30(12):3070-6. PubMed ID: 17848610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
    Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel AH; Karalliedde J; Mark PB; Patel DC; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
    BMC Nephrol; 2022 Jan; 23(1):9. PubMed ID: 34979961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
    Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
    BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.